Global ETD Search

1	Role of R-spondin-1 in the Regulation of β-cell Behaviour Wong, Victor Shing Chi 31 August 2011 (has links) R-spondin-1 (Rspo1) is an intestinal growth factor known to exert its effects through activation of the canonical Wnt (cWnt) pathway, but its function in the β-cell had not been explored. In Chapter 2, Rspo1 mRNA was found to be expressed in murine islets and the murine MIN6 and βTC β-cell lines, and Rspo1 protein was detected in MIN6 β-cells. Rspo1 activated cWnt signaling and induced insulin mRNA expression in MIN6 β-cells. Analysis of MIN6 and mouse β-cell proliferation revealed that Rspo1 stimulated cell growth and significantly abolished cytokine-induced cellular apoptosis. Rspo1 also stimulated insulin secretion in a glucose-independent fashion. Chapter 2 further demonstrated that the glucagon-like peptide-1 receptor agonist, exendin-4 (EX4), stimulated Rspo1 mRNA transcript levels in MIN6 cells in a glucose-, time-, dose- and PI3-kinase-dependent fashion. Together, these studies demonstrate that Rspo1 is a novel β-cell growth factor and insulin secretagogue that is regulated by EX4. In Chapter 3, the role of Rspo1 in β-cells in vivo was explored using Rspo1 knock-out (Rspo1-/-) mice. Rspo1-/- mice had normal fasting glycemia but an improved glycemic control after an oral glucose challenge compared to Rspo1+/+ mice, with no difference in insulin sensitivity but an enhanced insulin response over 30 min; glucagon responses were normal. Rspo1 deficiency also resulted in an increase in β-cell mass in association with an increase in Ki67-positive β-cells, a marker of proliferation, relative to Rspo1+/+ mice. Rspo1-/- pancreatic tissues also demonstrated a significant increase in the number of insulin-positive ductal cells, suggestive of β-cell neogenesis. Rspo1-/- islets displayed no changes in glucose-induced insulin secretion but showed a complete absence of glucose-induced suppression glucagon secretion. Treatment of Rspo1-/- mice for 2 wk with EX4 resulted in a similar glycemic profile to EX4-treated Rspo1+/+ mice after an oral glucose challenge, with no changes in insulin sensitivity. Interestingly, EX4 administration to Rspo1-/- normalized β-cell mass to a level comparable to that in Rspo1+/+ mice. Although further studies are required, the findings in this thesis reveal a novel role for Rspo1 as a regulator of β-cell behaviour in vivo, and suggest novel roles for Rspo1 in both a- and ductal-cells. R-spondin-1 β-cell Proliferation Apoptosis Insulin secretion Islet 0719
2	Role of R-spondin-1 in the Regulation of β-cell Behaviour Wong, Victor Shing Chi 31 August 2011 (has links) R-spondin-1 (Rspo1) is an intestinal growth factor known to exert its effects through activation of the canonical Wnt (cWnt) pathway, but its function in the β-cell had not been explored. In Chapter 2, Rspo1 mRNA was found to be expressed in murine islets and the murine MIN6 and βTC β-cell lines, and Rspo1 protein was detected in MIN6 β-cells. Rspo1 activated cWnt signaling and induced insulin mRNA expression in MIN6 β-cells. Analysis of MIN6 and mouse β-cell proliferation revealed that Rspo1 stimulated cell growth and significantly abolished cytokine-induced cellular apoptosis. Rspo1 also stimulated insulin secretion in a glucose-independent fashion. Chapter 2 further demonstrated that the glucagon-like peptide-1 receptor agonist, exendin-4 (EX4), stimulated Rspo1 mRNA transcript levels in MIN6 cells in a glucose-, time-, dose- and PI3-kinase-dependent fashion. Together, these studies demonstrate that Rspo1 is a novel β-cell growth factor and insulin secretagogue that is regulated by EX4. In Chapter 3, the role of Rspo1 in β-cells in vivo was explored using Rspo1 knock-out (Rspo1-/-) mice. Rspo1-/- mice had normal fasting glycemia but an improved glycemic control after an oral glucose challenge compared to Rspo1+/+ mice, with no difference in insulin sensitivity but an enhanced insulin response over 30 min; glucagon responses were normal. Rspo1 deficiency also resulted in an increase in β-cell mass in association with an increase in Ki67-positive β-cells, a marker of proliferation, relative to Rspo1+/+ mice. Rspo1-/- pancreatic tissues also demonstrated a significant increase in the number of insulin-positive ductal cells, suggestive of β-cell neogenesis. Rspo1-/- islets displayed no changes in glucose-induced insulin secretion but showed a complete absence of glucose-induced suppression glucagon secretion. Treatment of Rspo1-/- mice for 2 wk with EX4 resulted in a similar glycemic profile to EX4-treated Rspo1+/+ mice after an oral glucose challenge, with no changes in insulin sensitivity. Interestingly, EX4 administration to Rspo1-/- normalized β-cell mass to a level comparable to that in Rspo1+/+ mice. Although further studies are required, the findings in this thesis reveal a novel role for Rspo1 as a regulator of β-cell behaviour in vivo, and suggest novel roles for Rspo1 in both a- and ductal-cells. R-spondin-1 β-cell Proliferation Apoptosis Insulin secretion Islet 0719
3	Conformational analysis of peptides and proteins for drug design using molecular simulations Atzori, Alessio January 2015 (has links) The intrinsic plasticity of biological systems provides opportunities for rational design of selective and potent ligands. Increasingly, computational methods are being applied to predict biomolecular flexibility. However, the motions involved in these processes can be large and occur on time scales generally difficult to achieve with standard simulation methods. In order to overcome the intrinsic limitations of classical molecular dynamics, this Ph.D. project focuses on the application of advanced sampling computational techniques to capture the plasticity of diverse biological systems. The first of these applications involved the evaluation of the secondary structure of the N-terminal portion of p53 and its inverse, reverse and retro-inverso sequences by using replica exchange molecular dynamics simulations in implicit solvent. In this study, we also evaluated the effects of reversal of sequence and stereochemistry in mimicking an inhibitory pharmacophoric conformation. The results showed how the ability to mimic the parent peptide is severely compromised by backbone orientation (for D-amino acids) and side-chain orientation (for reversed sequences). Moreover, the structural information obtained from simulations showed good agreement with NMR and circular dichroism studies, confirming the validity of the combination of replica exchange molecular dynamics with the ff99SB force field and Generalized Born solvent model for computational modelling of D-peptide conformations.In a second work, we explored conformations of the DFG motif of the p38α mitogen-activated protein (MAP) kinase. To achieve this, we employed an advanced sampling simulation method that has been developed in-house, called swarm-enhanced sampling molecular dynamics (sesMD). In contrast to multiple independent MD simulations, swarm-coupled sesMD trajectories were able to sample a wide range of DFG conformations, some of which map onto existing crystal structures. Simulated structures intermediate between DFG-in and DFG-out conformations were predicted to have druggable pockets of interest for structure-based ligand design. Overall, sesMD shows promise as a useful tool for enhanced sampling of complex conformational landscapes. Finally, we used microsecond MD simulations to evaluate the molecular plasticity of R-spondins, a class of proteins involved in the activation of the Wnt pathway. The unbound R-spondin 1 is characterised by a closed conformation, while, when complexed to proteins LGR and RNF43/ZNRF3, assumes an open and more extended arrangement. This is true also for R-spondin 2, in both its unbound or bound forms. From our simulation, we find that the closed R-spondin 1 conformation is stable, whilst, R-spondin 1 and 2 from their open conformation explore several intermediate structures. In addition, we evaluated the druggability of a potential binding site located at the interface between the second and the third β-hairpin moiety of the first furin domain. The computational screening with small molecular fragments provided interesting insights about the druggability and the pharmacophoric features of the potential binding pockets identified, outlining promising future perspectives of structure-based design of Wnt pathway inhibitors. 615.1
4	Cell type-dependent differential activation of ERK by oncogenic KRAS or BRAF in the mouse intestinal epithelium Brandt, Raphael 10 March 2023 (has links) Kolorektale Karzinome (CRC) zeigen eine heterogene Ätiologie. Die Progression prämaligner Vorläufer zu CRC unterscheidet (U) sich in Morphologie, molekularen Veränderungen und Interaktion mit der Tumorumgebung. CRC weisen oft onkogene Mutationen in KRAS und BRAF auf. Diese steigern die MAPK Signalwegaktivität (Mpa). Obwohl sie im selben Signalweg wirken, sind KRAS und BRAF auf die CRC-Entitäten U verteilt. Dabei ist KRAS häufiger im sogenannten konventionellen und BRAF im serratierten Weg zu CRC mutiert. In dieser Studie nutzte ich murine intestinale Organoide (iO), die induzierbare (Ind) KRAS oder BRAF Onkogene exprimieren. Große U zwischen KRAS und BRAF zeigten sich sowohl in Signaltransduktion (ST) als auch im Phänotyp. Phosphoprotein-, ERK-Reporter-, scRNA-Seq und EM-Analysen ergaben eine starke Mpa durch BRAF, die zu hoher Expression von MAPK-Zielgenen und Verlust der epithelialen Integrität führte. iO nach KRAS-Ind blieben intakt, korrelierend mit moderater, zelltypspezifischer (ZS) Mpa in sekretorischen und undifferenzierten Zellen. Die meisten Enterozyten waren Mpa-negativ. ERK-Reporter zeigten: Das ZS Muster der Mpa ist nicht nur gegenüber KRAS, sondern auch dem Entzug von Wachstumsfaktoren stabil. Dies spricht für eine intrinsische, robuste Regulierung der Mpa. BRAF-Ind Mpa setzte die ZS Regulierung der MAPK außer Kraft und schädigte das Gewebe, im Einklang mit einer oberen Grenze tolerabler Mpa. Die ZS Mpa wurde in CRC-Zelllinien bestätigt, deren Mpa durch KRAS aber nicht BRAF U ausfiel. Ferner, nutzte ich iO mit bCatenin+KRAS-Ind, um den konventionellen Weg zu CRC zu modellieren. Die Kombination führte zu synergistischen Effekten, die sich in EGFR-unabhängigem Wachstum und der Aufhebung der ZS Mpa-Blockade äußerten, die durch eine Verschiebung der Differenzierung zu mehr Progenitorzellen bewirkt wurde. Zusammenfassend konnte ich U in der Mpa durch KRAS oder BRAF im Darmepithel feststellen, was dazu beiträgt, deren Rollen in der CRC-Genese zu bestimmen. / Colorectal cancer (CRC) is a disease with heterogeneous etiology. Premalignant lesions follow distinct routes of progression to carcinoma reflected by differences in morphology, molecular alterations and the tumor environment. Mutant KRAS and BRAF are frequent, leading to MAPK pathway activation (Mpa), which is relevant for CRC therapy. Despite acting in the same pathway, mutant KRAS and BRAF segregate to different entities, as KRAS is more frequent in the conventional- and BRAF being specific for the serrated route to CRC. I used murine intestinal organoids (iO) expressing inducible oncogenic KRAS or BRAF to study the impact of oncogenes in primary cells. I found marked differences in signal transduction and phenotype. Phospho-protein, ERK-reporter, scRNA-seq and EM data showed strong Mpa upon BRAF induction followed by ERK-target gene expression leading to tissue disruption. In contrast, KRAS left the tissue intact resulting in less and cell type-dependent Mpa limited to secretory cells, a subset of late-stage enterocytes and undifferentiated crypt cells. Most enterocytes were irresponsive to KRAS. The pattern of Mpa was robust towards KRAS or growth factor depletion arguing in favor of intrinsic, resilient MAPK regulation. In iO, BRAF-induced Mpa could break this cell type-specific regulation, indicating an upper limit of tolerable Mpa. I validated these findings in CRC cell lines that differed in Mpa in response to oncogenic KRAS but not BRAF. Finally, I used iO expressing an inducible form of stabilized bCatenin in combination with KRAS to mimic events frequently found in the conventional pathway to CRC. Expression of KRAS and bCatenin synergized in driving EGFR independent growth and breaking the villus-specific block of Mpa by altering differentiation towards progenitor cell types. In summary, this study emphasizes differences between Mpa induced by oncogenic KRAS or BRAF which helps clarifying their nature in different etiological routes to CRC genesis. KRAS KRASG12V BRAF BRAFV600E EGFR EGF MAPK ERK FIRE Reporter MEK MAPKK MAPKKK beta-Catenin intestinale Organoidkultur intestinale Organoide Mausmodelle von Tumoren kolorektales Karzinom kolorektale Karzionome CRC Primärzellen Tumormodelle Onkogene oncogenes KRAS oncogenes BRAF onkogene Signaltransduktion 3D Modell matrigel R-spondin RSPO Noggin KRAS KRASG12V BRAF BRAFV600E EGFR EGF MAPK ERK FIRE reporter MEK MAPKK MAPKKK beta-Catenin intestinal organoid intestinal organoids intestinal organoid culture murine model of cancer colorectal carcinoma CRC primary tumor model oncogenes oncogenic KRAS oncogenic BRAF 3D model matrigel R-spondin RSPO Noggin 610 Medizin und Gesundheit ddc:610

1

Page generated in 0.0392 seconds